Association study of onset age, attempted suicide, aggressive behavior, and schizophrenia with a serotonin 1B receptor (A-161T) genetic polymorphism

被引:26
作者
Hong, CJ
Pan, GM
Tsai, SJ
机构
[1] Taipei Vet Gen Hosp, Dept Psychiat, Taipei 11217, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Div Psychiat, Taipei 112, Taiwan
关键词
association study; polymorphism; serotonin 1B receptor; schizophrenia; aggression; suicide;
D O I
10.1159/000075330
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Located on the presynaptic and postsynaptic terminals of serotonergic neurons, serotonin 1B receptors (5-HT1B) are involved in the modulation of serotonergic activity. The implications of 5-HT1B study of animal models of schizophrenia and antipsychotic activity involving defective sensory processes suggest that this receptor may be involved in the pathogenesis of schizophrenic disorders. In a population-based association study, we tested the hypothesis that the allelic variant, A-161T, of the 5-HT1B gene confers susceptibility to schizophrenic disorders and is associated with age of onset, aggressive behavior and attempted suicide. We genotyped the A-161T polymorphism in 110 patients with schizophrenic disorders and in 215 normal controls. No association was demonstrated between 5-HT1B genotype or allele frequencies and schizophrenic disorders, except for a trend for later age at disease onset in A/A homozygote schizophrenics in comparison with A/T heterozygote patients (p = 0.071). No significant difference in genotype distribution was determined comparing patients with and without aggressive behavior, and those with and without a history of suicide attempt. These findings suggest that the investigated 5-HT1B genetic polymorphism does not play a major role in the pathogenesis of schizophrenic disorders. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 14 条
[1]  
Abi-Dargham A, 1997, J NEUROPSYCH CLIN N, V9, P1
[2]   Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)1B and h5-HT1D receptors [J].
Audinot, V ;
Newman-Tancredi, A ;
Cussac, D ;
Millan, MJ .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (03) :410-422
[3]   Modulation of dopamine release in the nucleus accumbens by 5-HT1B agonists: Involvement of the hippocampo-accumbens pathway [J].
Boulenguez, P ;
Rawlins, JNP ;
Chauveau, J ;
Joseph, MH ;
Mitchell, SN ;
Gray, JA .
NEUROPHARMACOLOGY, 1996, 35 (11) :1521-1529
[4]   SEROTONIN, SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUG-ACTION [J].
BREIER, A .
SCHIZOPHRENIA RESEARCH, 1995, 14 (03) :187-202
[5]   THE CURRENT STATUS OF THE DOPAMINE HYPOTHESIS OF SCHIZOPHRENIA [J].
CARLSSON, A .
NEUROPSYCHOPHARMACOLOGY, 1988, 1 (03) :179-186
[6]   Serotonin(1B) receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin(1B) knockout mice [J].
Dulawa, SC ;
Hen, R ;
ScearceLevie, K ;
Geyer, MA .
PSYCHOPHARMACOLOGY, 1997, 132 (02) :125-134
[7]   SEROTONIN RECEPTORS - CLINICAL IMPLICATIONS [J].
GLENNON, RA .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1990, 14 (01) :35-47
[8]   Relationship of psychopathology to the human serotonin1B genotype and receptor binding kinetics in postmortem brain tissue [J].
Huang, YY ;
Grailhe, R ;
Arango, V ;
Hen, R ;
Mann, JJ .
NEUROPSYCHOPHARMACOLOGY, 1999, 21 (02) :238-246
[9]  
LINNOILA M, 1986, CLIN NEUROPHARMACOL, V9, P377
[10]   The possible role of 5-HT1B/D receptors in psychiatric disorders and their potential as a target for therapy [J].
Moret, C ;
Briley, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) :1-12